LVEFmonitoring1yearEverymonthPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)CapecitabineTC (docetaxel /cyclophosphamide)10yearsRadiationtherapyTaxanesExemestaneTNBCPembrolizumabPertuzumabAromataseinhibitorsAbemaciclibTDM-1(Ado-trastuzumabemtansine)OlaparibLoperamideprophylaxisTamoxifenAnthracyclinesChemoendocrinetherapy2yearsVenlafaxineIntermediate(11-25)LVEFmonitoring1yearEverymonthPercentageneeded to beconsidered HR+(adjuvantendocrine therapyconsidered)CapecitabineTC (docetaxel /cyclophosphamide)10yearsRadiationtherapyTaxanesExemestaneTNBCPembrolizumabPertuzumabAromataseinhibitorsAbemaciclibTDM-1(Ado-trastuzumabemtansine)OlaparibLoperamideprophylaxisTamoxifenAnthracyclinesChemoendocrinetherapy2yearsVenlafaxineIntermediate(11-25)

Early-Stage Breast Cancer - Call List

(Print) Use this randomly generated list as your call list when playing the game. There is no need to say the BINGO column name. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
  1. LVEF monitoring
  2. 1 year
  3. Every month
  4. Percentage needed to be considered HR+ (adjuvant endocrine therapy considered)
  5. Capecitabine
  6. TC (docetaxel / cyclophosphamide)
  7. 10 years
  8. Radiation therapy
  9. Taxanes
  10. Exemestane
  11. TNBC
  12. Pembrolizumab
  13. Pertuzumab
  14. Aromatase inhibitors
  15. Abemaciclib
  16. TDM-1 (Ado-trastuzumab emtansine)
  17. Olaparib
  18. Loperamide prophylaxis
  19. Tamoxifen
  20. Anthracyclines
  21. Chemoendocrine therapy
  22. 2 years
  23. Venlafaxine
  24. Intermediate (11-25)